Nutromics today announced the appointment of Thomas (Tom) M. Prescott as chair of its board, bringing deep U.S. medtech commercialization experience as the company enters a pivotal new phase. The appointment comes as Nutromics prepares to open its Series B round and advances toward its planned U.S. commercial launch in 2027. The news follows major recent milestones, including strong clinical performance in recent ICU studies and a February 2026 publication in Nature Biotechnology.
Prescott is one of the most experienced operators in medtech, with a track record of building and scaling businesses across U.S. and global healthcare systems in the medtech industry. He served as president and chief executive officer of Align Technology from 2002 to 2015, during which market capitalization increased from $240 million to $4.4 billion. Prior to Align, he was president and chief executive officer of Cardiac Pathways until its acquisition by Boston Scientific, and earlier held senior leadership roles at Nellcor Puritan Bennett, along with related roles at GE Medical Systems and Siemens.
Nutromics has developed a wearable platform designed to continuously monitor clinically important drugs and biomarkers in real time, giving clinicians a more timely and complete picture than is possible with today’s intermittent testing methods. Its first product is aimed at improving dosing for the antibiotic vancomycin in hospitals, including reducing toxic side effects. The second product targets sepsis detection and management, where continuous monitoring could deliver significant clinical benefits not achievable with today’s technology.
Together, these initial applications point to a much broader platform opportunity. Continuous glucose monitoring showed how powerful real-time data can be when it replaces delayed, intermittent snapshots. Nutromics is now taking that model beyond glucose and leading the emerging field of continuous molecular monitoring.
Commenting on his decision to join Nutromics, Prescott said: “What drew me to Nutromics is the team. The platform they have created can help close critical gaps in patient monitoring across virtually all sites of care. Those gaps can drive significant costs and less than optimal patient outcomes, which explains the sharp focus on that market. Due to the flexibility of the technology, an equally large, longer-term opportunity is the emerging wellness-driven consumer market for high performance wearables. Until now, the technology has not existed to continuously monitor a range of high value biomarkers. Opportunities to help a team define a new category, enable better patient outcomes at lower costs to the healthcare system, while building scale are rare. I am honored to join this team.”
Peter Vranes, CEO and co-founder of Nutromics, said: “Tom is joining Nutromics at exactly the right time. We have built the platform, materially de-risked the technology, and now have strong confidence in the readiness of our first product as we move toward commercialization. What makes Nutromics especially exciting is that the first product is just the beginning. Tom’s experience helping build important new product categories at companies such as Align and Nellcor is highly relevant as we move toward U.S. commercial launch.”
Nutromics is currently working with leading U.S. hospitals, health systems, and academic medical centers on clinical studies as it advances toward formal partnerships, launch readiness, and early commercial adoption.
Nutromics’ investors include Dexcom, a global leader in continuous glucose monitoring technology. Prescott succeeds Dr. Chris Roberts AO as chair. Dr. Roberts will remain on the board as a non-executive director to support continuity through the company’s next phase.
About Nutromics
Nutromics is an Australian-founded advanced monitoring company that has built a wearable, DNA-based platform for continuous molecular monitoring. Its electrochemical aptamer-based sensors, integrated with minimally invasive microneedles, are designed to sense multiple proteins, drugs, metabolites, and hormones in real time. Nutromics is advancing toward regulatory clearance and commercial launch of its first product, with operations in Australia and the United States. The company’s vision is a world with zero preventable deaths due to a lack of continuous molecular monitoring. For more information, visit www.nutromics.com.
Media Contact
Royina Bakshi Lock
Nutromics
roy.bakshi@nutromics.com
